{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:47:54Z","timestamp":1792673274994,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","award":["Chugai Pharmaceutical"],"award-info":[{"award-number":["Chugai Pharmaceutical"]}],"id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001695","name":"Japan Science and Technology Corporation","doi-asserted-by":"publisher","award":["JPMJPF2017"],"award-info":[{"award-number":["JPMJPF2017"]}],"id":[{"id":"10.13039\/501100001695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP256f0137008"],"award-info":[{"award-number":["JP256f0137008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03226-5","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:21:17Z","timestamp":1792671677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcome sub-analysis of a phase 2 trial of bladder preservation therapy with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer"],"prefix":"10.1007","author":[{"given":"Bryan J.","family":"Mathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-4791","authenticated-orcid":false,"given":"Yoshiyuki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuo","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yoshio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamasa","family":"Yoshitake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyonori","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3226_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1597107","volume":"15","author":"H Huang","year":"2025","unstructured":"Huang H, Hao H, Du J et al (2025) A nomogram for predicting overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy: a retrospective cohort study. Front Oncol 15:1597107","journal-title":"Front Oncol"},{"issue":"6","key":"3226_CR2","doi-asserted-by":"publisher","first-page":"3073081","DOI":"10.21037\/tau.2020.03.23","volume":"9","author":"K Aminoltejari","year":"2020","unstructured":"Aminoltejari K, Black PC (2020) Radical cystectomy: a review of techniques, developments and controversies. Transl Androl Urol 9(6):3073081\u20133073081","journal-title":"Transl Androl Urol"},{"issue":"2","key":"3226_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-26-515984","volume":"46","author":"J Li","year":"2026","unstructured":"Li J, Ballas L, Ghatalia P (2026) Bladder preservation strategies in muscle-invasive bladder cancer. Am Soc Clin Oncol Educ Book 46(2):e515984","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"3226_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jval.2013.01.005","volume":"16","author":"JE Bekelman","year":"2013","unstructured":"Bekelman JE, Handorf EA, Guzzo T et al (2013) Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research. Value Health 16(4):610\u2013618","journal-title":"Value Health"},{"issue":"1","key":"3226_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijrobp.2023.07.027","volume":"118","author":"K Br\u00fcck","year":"2024","unstructured":"Br\u00fcck K, Meijer RP, Boormans JL et al (2024) Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study. Int J Radiat Oncol Biol Phys 118(1):41\u201349","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"3226_CR6","doi-asserted-by":"publisher","first-page":"2997006","DOI":"10.21037\/tau.2020.02.01","volume":"9","author":"H Choi","year":"2020","unstructured":"Choi H, Park JY, Bae JH et al (2020) Health-related quality of life after radical cystectomy. Transl Androl Urol 9(6):2997006\u20132993006","journal-title":"Transl Androl Urol"},{"issue":"3","key":"3226_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","volume":"81","author":"MB Clements","year":"2022","unstructured":"Clements MB, Atkinson TM, Dalbagni GM et al (2022) Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur Urol 81(3):294\u2013304","journal-title":"Eur Urol"},{"issue":"4","key":"3226_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ijrobp.2025.06.3866","volume":"123","author":"K Br\u00fcck","year":"2025","unstructured":"Br\u00fcck K, Atema V, Leliveld AM et al (2025) Health-related quality of life in patients treated for nonmetastatic muscle-invasive bladder cancer: radical cystectomy versus bladder-preserving therapy. Int J Radiat Oncol Biol Phys 123(4):1004\u20131017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3226_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000435","volume":"3","author":"V Murthy","year":"2024","unstructured":"Murthy V, Kashid SR, Pal M et al (2024) Prospective comparative study of quality of life in patients with bladder cancer undergoing cystectomy with ileal conduit or bladder preservation. BMJ Oncol 3(1):e000435","journal-title":"BMJ Oncol"},{"key":"3226_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.12.019","author":"Y Nagumo","year":"2026","unstructured":"Nagumo Y, Kimura T, Ishikawa H et al (2026) Bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: final analysis from a multicentre, open-label, prospective phase 2 trial. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.019","journal-title":"Eur Urol"},{"issue":"3","key":"3226_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","volume":"117","author":"T Kimura","year":"2023","unstructured":"Kimura T, Ishikawa H, Nagumo Y et al (2023) Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase 2 trial. Int J Radiat Oncol Biol Phys 117(3):644\u2013651","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3226_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2021.100724","volume":"21","author":"Y Sekino","year":"2021","unstructured":"Sekino Y, Ishikawa H, Kimura T et al (2021) Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART)\u2014a study protocol for an open-label, phase II, multicenter study. Contemp Clin Trials Commun 21:100724","journal-title":"Contemp Clin Trials Commun"},{"issue":"8","key":"3226_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T (2021) Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health 24(8):1193\u20131202","journal-title":"Value Health"},{"issue":"6","key":"3226_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.5980\/jpnjurol1989.93.669","volume":"93","author":"Y Homma","year":"2010","unstructured":"Homma Y, Tsukamoto T, Yasuda K et al (2010) Linguistic validation of Japanese version of international prostate symptom score and BPH impact index. Jpn J Urol 93(6):669","journal-title":"Jpn J Urol"},{"issue":"2","key":"3226_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome\u2014overactive bladder symptom score. Urology 68(2):318\u2013323","journal-title":"Urology"},{"issue":"6","key":"3226_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/bco2.339","volume":"5","author":"J Lahoud","year":"2024","unstructured":"Lahoud J, Patel MI, Naher S et al (2024) A systematic review of the patient reported outcomes that affect patients with muscle invasive bladder cancer after radical cystectomy and urinary diversion. BJUI Compass 5(6):638\u2013654","journal-title":"BJUI Compass"},{"issue":"2","key":"3226_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","volume":"77","author":"RA Huddart","year":"2020","unstructured":"Huddart RA, Hall E, Lewis R et al (2020) Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy \u00b1 chemotherapy in the BC2001 phase III randomised controlled trial. Eur Urol 77(2):260\u2013268","journal-title":"Eur Urol"},{"issue":"5","key":"3226_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1442-2042.2008.02032.x","volume":"15","author":"K Hashine","year":"2008","unstructured":"Hashine K, Miura N, Numata K et al (2008) Health\u2010related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Int J Urol 15(5):403\u2013406","journal-title":"Int J Urol"},{"issue":"5","key":"3226_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","volume":"96","author":"KS Mak","year":"2016","unstructured":"Mak KS, Smith AB, Eidelman A et al (2016) Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96(5):1028\u20131036","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3226_CR20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13246","volume":"23","author":"K Nishihara","year":"2022","unstructured":"Nishihara K, Ueda K, Kurose H et al (2022) Survival outcomes of non-definitive therapy for muscle-invasive bladder cancer. Oncol Lett 23(4):126","journal-title":"Oncol Lett"},{"issue":"3","key":"3226_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.22465\/juo.244801000050","volume":"22","author":"Y Jo","year":"2024","unstructured":"Jo Y, Yuk HD (2024) Trimodal therapy in the treatment of muscle-invasive bladder cancer. J Urol Oncol 22(3):256\u2013267","journal-title":"J Urol Oncol"},{"key":"3226_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110038","volume":"190","author":"G Francolini","year":"2024","unstructured":"Francolini G, Ghoshal A, Caini S et al (2024) Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis. Radiother Oncol 190:110038","journal-title":"Radiother Oncol"},{"issue":"5","key":"3226_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bju.13900","volume":"120","author":"RA Huddart","year":"2017","unstructured":"Huddart RA, Birtle A, Maynard L et al (2017) Clinical and patient\u2010reported outcomes of SPARE \u2013 a randomised feasibility study of selective bladder preservation versus radical cystectomy. BJU Int 120(5):639\u2013650","journal-title":"BJU Int"},{"issue":"5","key":"3226_CR24","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/j.clon.2023.02.005","volume":"35","author":"L Philipps","year":"2023","unstructured":"Philipps L, Porta N, James N et al (2023) Differences in quality of life and toxicity for male and female patients following chemo(radiotherapy) for bladder cancer. Clin Oncol 35(5):e336\u2013e343","journal-title":"Clin Oncol"},{"issue":"4","key":"3226_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bju.16821","volume":"136","author":"MB Clements","year":"2025","unstructured":"Clements MB, Pekala KR, Tin AL et al (2025) Prospective health\u2010related quality of life in women undergoing radical cystectomy and urinary diversion. BJU Int 136(4):728\u2013737","journal-title":"BJU Int"},{"issue":"6","key":"3226_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5489\/cuaj.4877","volume":"12","author":"AL Nayak","year":"2017","unstructured":"Nayak AL, Cagiannos I, Lavall\u00e9e L et al (2017) Urinary function following radical cystectomy and orthotopic neobladder urinary reconstruction. Can Urol Assoc J 12(6):181\u2013186","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"3226_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00192-012-1818-8","volume":"24","author":"S-M Hsiao","year":"2013","unstructured":"Hsiao S-M, Lin H-H, Kuo H-C (2013) International prostate symptom score for assessing lower urinary tract dysfunction in women. Int Urogynecol J 24(2):263\u2013267","journal-title":"Int Urogynecol J"},{"issue":"6","key":"3226_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.urology.2009.01.054","volume":"73","author":"K Okamura","year":"2009","unstructured":"Okamura K, Nojiri Y, Osuga Y et al (2009) Psychometric analysis of international prostate symptom score for female lower urinary tract symptoms. Urology 73(6):1199\u20131202","journal-title":"Urology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03226-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03226-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03226-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:21:19Z","timestamp":1792671679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03226-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":28,"alternative-id":["3226"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03226-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yoshiyuki Nagumo received a grant from Chugai Pharmaceutical Co, Ltd. Tomokazu Kimura received a grant from Chugai Pharmaceutical Co, Ltd. Hiroyuki Nishiyama received honoraria from Astellas Pharma., Bristol Myers Squibb, Janssen Pharmaceutical K.K., MSD K.K., Ono Pharmaceutical Co., Ltd, and Pfizer Inc., and a grant from Chugai Pharmaceutical Co, Ltd and Astellas Pharma. Toyonori Tsuzuki received honoraria from AstraZeneca, Merk Biopharma, Ono Pharmaceutical Co., Ltd, Bristol Myers Squibb, Nippon Kayaku Co., Ltd., Janssen Pharmaceutical K.K., and a grant from SBI Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Ferring Pharmaceuticals. Koichi Hashimoto received a grant from Chugai Pharmaceutical Co. and Ono Pharmaceutical Co. The other authors have no conflicts to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki or its equivalents. Written, informed consent, including consent for inclusion into this sub-analysis, was obtained from all patients. The study protocol was registered in the Japan Registry of Clinical Trials (jRCT2031180060) and approved by the University of Tsukuba Institutional Review Board.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}